Zhejiang Hisun Pharmaceutical
GPTKB entity
Statements (60)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Ali_Health
|
| gptkbp:acquisition |
gptkb:Jiangsu_Hengrui_Medicine
Hubei Huitian Pharmaceutical |
| gptkbp:awards |
gptkb:National_Science_and_Technology_Progress_Award
|
| gptkbp:ceo |
gptkb:Zhang_Jian
|
| gptkbp:certification |
gptkb:standard
GMP |
| gptkbp:clinical_trial |
ongoing
|
| gptkbp:collaborations |
academic institutions
international organizations |
| gptkbp:community_involvement |
scholarships
disaster relief efforts education programs healthcare initiatives volunteer programs health awareness campaigns |
| gptkbp:employees |
over 10,000
|
| gptkbp:exported_to |
to over 50 countries
|
| gptkbp:founded |
gptkb:1995
|
| gptkbp:global_presence |
gptkb:Africa
gptkb:Europe gptkb:Asia gptkb:Latin_America gptkb:North_America |
| gptkbp:headquarters |
gptkb:Zhejiang,_China
|
| https://www.w3.org/2000/01/rdf-schema#label |
Zhejiang Hisun Pharmaceutical
|
| gptkbp:industry |
gptkb:drug
|
| gptkbp:innovation |
gptkb:Company
|
| gptkbp:invention |
over 200
|
| gptkbp:investment |
R& D
|
| gptkbp:market |
global
|
| gptkbp:market_cap |
approximately 5 billion USD
|
| gptkbp:partnership |
gptkb:Pfizer
local governments |
| gptkbp:product_line |
antibiotics
vaccines hormonal therapies ophthalmic products nutraceuticals oncology drugs cardiovascular drugs respiratory drugs diabetes medications dermatological products OTC products CNS drugs gastrointestinal drugs pain management drugs |
| gptkbp:products |
generic drugs
active pharmaceutical ingredients |
| gptkbp:research_focus |
oncology
cardiovascular diseases anti-infectives |
| gptkbp:revenue |
over 1 billion USD
|
| gptkbp:subsidiary |
Hisun Biopharmaceutical
|
| gptkbp:sustainability |
environmental practices
|
| gptkbp:symbol |
600267
|
| gptkbp:website |
www.hisunpharm.com
|